2020, Vol. 8, Issue 1, Part A

Objectives: Determine safety of Nigella Sativa on clinical and biochemical parameters among patients with dyslipidemia.

Subjects and Methods: The study is double blinded trial that was conducted in Family practice clinic, 19 patients were included in intervention group and 19 in control. Intervention group received their routine therapy for dyslipidemia (statins) in addition to crushed nigella sativa seeds daily for 6 weeks. Control group received their routine in addition to placebo. The baseline blood pressure, fasting blood sugar, liver transaminases and serum creatinine were measured before the trial and repeated after 6 weeks.

Results: The patients in the intervention group had significantly lower creatinine level (p=0.037) after intervention. B.P. fasting blood sugar, liver transaminases and serum creatinine measures between both intervention and control groups were not statistically significant after adding nigella sativa. Favorable impact of N. sativa was noted on almost all measures in intervention group but were not statistically significant when compared to control group.

Conclusion: Adding N. sativa to therapy for dyslipidemia is safe on B.P., blood sugar, liver and kidney function tests.